|Day Low/High||118.75 / 126.01|
|52 Wk Low/High||50.68 / 176.50|
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
This is a battleground stock that has made big moves in both directions on earnings in the past.
The pressure on financials is affecting the entire market.
If you are interested in Square longer term be patient and wait for the drama to end.
The stock still needs to do more work to be convincing.
I'm not yet convinced that this poor action is the start of a major change in market character.
Blue chip name PEP is a good example of the weak action in individual stocks.
It's an interesting story but there are better places for your funds.
This options trade gives the position plenty of time to work.
Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.
It is the poster boy for the havoc that internet retailers have wrecked on brick and mortar retailers.
The indices are being jerked around on some news headlines today.
After recent weakness in the biotech sector, here are some names to start watching.
Building on PPMD's 10-Year-Old Duchenne Registry, the largest Patient Reported Outcomes Registry for the Disease, and Sarepta Therapeutics' Leadership with the First U.S.-Approved Therapy, New Interchange is Scheduled for 2019 Launch
This is a healthy pullback in a market that was a little overheated.
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
You don't have to be Sigmund Freud to understand the psychology here.
If estimates continue to come up there will be institutional interest in the stock.
There are several key points to keep in mind as you digest this news.
If the market wanted an excuse to sell off it had it.
After rallying to more than $100 a share, the stock could pull back to around $95 before consolidating gains.
The market has wanted to sell-off for a while and finally it is doing it.
While markets are higher Tuesday, there is little to suggest recent choppy action won't continue.
The bounce this morning is producing a sigh of relief, but this is going to remain a difficult trading market.
For a long time now one of the most consistent patterns in the market has been buying dips created by negative headlines.
Apple in particular is helping the bullish cause.
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and non-profit CureDuchenne announced today they have...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.